GENMAB’S BLOCKBUSTER COCKTAIL YEARS (ADD, 19% UPSIDE)
15/03/19 -"The last one year has been a roller-coaster ride for the pure-play biotech, Genmab (Add, Denmark). While an R&D setback (two studies discontinued) in May 2018 triggered a sell-off, management’s ..."
Pages
49
Language
English
Published on
15/03/19
You may also be interested by these reports :
17/04/24
Q1 sales exceeded expectations, driven by a strong performance from the Companion Animal segment. The Farm Animal segment was however held back by a ...
16/04/24
Preview: Positive 1Q24 driven by clinical developments of portfolio companies
15/04/24
Investor appetite for Merck KGaA (Add, Germany) shares has been somewhat subdued since we last teased the name (15/03/2021). At that time, the ...
15/04/24
Turnaround story on track – TP increased to CHF 30.00 (from CHF 25.00) – Add reiterated